GLP-3R Triple Agonist
Analytical results for lot RET20VCS0326 (10 mL vial), third-party tested by AxisPharm, LLC and reported 2026-03-25.
| Assay | Method | Result |
|---|---|---|
| Purity | HPLC-UV (208 nm) | >99.3% |
| Identity | LC-MS (ESI+) | 2369.4 [M+2H], 1579.5 [M+3H] |
| Endotoxin | LAL assay | 0.051 EU/mg |
Lot record
| Lot number | RET20VCS0326 |
|---|---|
| Compound | GLP-3R Triple Agonist |
| Format | 10 mL vial |
| Label claim | 20 mg |
| Measured content | 20.1 mg |
| Expected mass | 4731.3 g/mol |
| Report date | 2026-03-25 |
| Sample received | 2026-03-25 |
| Manufactured | 2026-03 |
| Best before | 2028-03 |
| Manufacture | GMP-compliant peptide manufacturing facility, United States |
| Third-party analysis | AxisPharm, LLC |
| Status | Current — in stock |
Compound
A synthetic triple agonist at GLP-1, GIP and glucagon receptors, studied in multi-receptor incretin research.
GLP-3R Triple Agonist specification →Other lots of GLP-3R Triple Agonist
Lot-to-lot comparison across releases.
The certificate for this lot
The results above are published in full. The certificate itself is the testing laboratory’s document, and we supply it per batch rather than as a public download — so a certificate can only ever travel with the material it describes. If you hold or are purchasing lot RET20VCS0326, request it and we will send it.
Request the certificate for RET20VCS0326 →All compounds supplied by BioIntegrity are intended strictly for laboratory research and educational use. Not for human or animal consumption. Not for diagnostic, therapeutic, or clinical use. No statement on this website has been evaluated by the Food and Drug Administration. Purchaser affirms that products are acquired solely for legitimate laboratory research and assumes full responsibility for lawful handling, storage, and disposal.